Refine
Has Fulltext
- yes (23)
Is part of the Bibliography
- yes (23) (remove)
Year of publication
- 2020 (23) (remove)
Document Type
- Journal article (12)
- Doctoral Thesis (11)
Keywords
- DNA damage (3)
- Inhibition (2)
- 6-benzylaminopurine (1)
- A2B adenosine receptor (1)
- A2BAR (1)
- Adenosinrezeptor (1)
- Adipositaschirurgie (1)
- Alzheimers disease (1)
- Angiotensin II (1)
- Bestrahlung (1)
- Beta-Rezeptor (1)
- Brustkrebs (1)
- CAMP production (1)
- CIB1 (1)
- Carcinogenese (1)
- Chemokine receptors (1)
- Chemotherapie (1)
- DNA damage response (1)
- Dimerisierung (1)
- Dioscorea (1)
- ERK Dimerisierungsdefizienz (1)
- ERK-Monomer (1)
- ERK1/2 (1)
- ERK1/2 Dimerisierung (1)
- ERK2d4 (1)
- Erythrozyt (1)
- FRET sensors (1)
- Fettsucht (1)
- Förster Resonance Energy Transfer (1)
- G protein coupled receptor (GPCR) (1)
- G protein-coupled receptor kinase (1)
- G protein-coupled receptors (1)
- G-protein coupled receptor (1)
- GPCR dimerisation (1)
- GPCR signaling (1)
- Genomschaden (1)
- HAD-Phosphatasen (1)
- Hals-Nasen-Ohren-Tumor (1)
- Heart failure (1)
- Hemmung der Proliferation schnell wachsender Krebszellen (1)
- Herzinsuffizienz (1)
- Kleinkern (1)
- Kopf-Hals-Tumor (1)
- Krebs (1)
- Lymphozyt (1)
- MAP-Kinase (1)
- Magenchirurgie (1)
- Melanocortin 4 receptor (MC4R) (1)
- Melanocyte stimulating hormones MSH (1)
- Mikrokern (1)
- Mundschleimhaut (1)
- Neuronale (1)
- PDXP (1)
- PLP (1)
- Peptides (1)
- PhD thesis pharmacology (1)
- Phosphatasen (1)
- Pyridoxalphosphat (1)
- Raf kinase inhibitor protein (1)
- Raf-Kinasen (1)
- ST-elevation myocardial infarction (1)
- Strahlentherapie (1)
- Toxizität (1)
- Tumorzellproliferation (1)
- Vitamin B6 (1)
- Vitamin B6 Metabolismus (1)
- Vitamin-B6-Stoffwechsel (1)
- adenosine receptors (1)
- ageing (1)
- angiotensin II (1)
- antibody/autoantibody (1)
- assay (1)
- association (1)
- bariatric surgery (1)
- base excision repair (incision activity) (1)
- beta-adrenerge Signalwege (1)
- biased signaling (1)
- binding affinity (1)
- bioactive compounds (1)
- blood coagulation factor XIII (1)
- buccal mucosa (1)
- calmodulin (1)
- cardiac magnetic resonance imaging (1)
- cell fate (1)
- chalcone (1)
- child health (1)
- chromosomal damage (1)
- chronic heart failure (1)
- chronophin (1)
- cognitive impairment (1)
- conformational auto-epitope (1)
- coumarin (1)
- cyclic peptides/cyclopeptides (1)
- cyclopeptide therapy (1)
- cytokinins (1)
- cytome biomarkers (1)
- diagnosis (1)
- docking (1)
- etoposide (1)
- exposure (1)
- fluorescent probes (1)
- genomic damage (1)
- haloacid dehalogenase (1)
- head and neck cancer (1)
- healing and remodelling processes (1)
- homodimerization (1)
- induzierte Phosphatasen MKP-1 und MKP-2 (1)
- intracellular calcium release (1)
- kardiale Hypertrophie (1)
- life (1)
- live imaging (1)
- liver (1)
- maintenance of genomic integrity (1)
- micronuclei (1)
- micronucleus (1)
- mycotoxin (1)
- neurodegenerative diseases (1)
- neuronal (1)
- nutritional composition (1)
- obesity (1)
- occurrence (1)
- opioid ligands (1)
- opioid receptor (1)
- peripheral lymphocytes (1)
- peripheral-blood lymphocytes (1)
- phopohrylierungsdefizient (1)
- poly(ADP-ribosyl)ation (1)
- pyridoxal phosphatase (1)
- pyridoxal phosphate (1)
- radiation (1)
- red blood cells (1)
- reduction of ERK1/2 phosphorylation (1)
- reduction of cells proliferation (1)
- sex (1)
- single-molecule imaging (1)
- single-molecule microscopy (1)
- sub-Saharan Africa (1)
- therapeutic potential (1)
- toxicity (1)
- vitamin B6 (1)
- yam (1)
- β1-adrenoceptor/β1-adrenergic receptor (1)
Institute
- Institut für Pharmakologie und Toxikologie (23) (remove)
Sonstige beteiligte Institutionen
μ‐Opioid receptors (μ‐ORs) play a critical role in the modulation of pain and mediate the effects of the most powerful analgesic drugs. Despite extensive efforts, it remains insufficiently understood how μ‐ORs produce specific effects in living cells. We developed new fluorescent ligands based on the μ‐OR antagonist E‐p‐nitrocinnamoylamino‐dihydrocodeinone (CACO), that display high affinity, long residence time and pronounced selectivity. Using these ligands, we achieved single‐molecule imaging of μ‐ORs on the surface of living cells at physiological expression levels. Our results reveal a high heterogeneity in the diffusion of μ‐ORs, with a relevant immobile fraction. Using a pair of fluorescent ligands of different color, we provide evidence that μ‐ORs interact with each other to form short‐lived homodimers on the plasma membrane. This approach provides a new strategy to investigate μ‐OR pharmacology at single‐molecule level.
Metabolism and signaling of cytokinins was first established in plants, followed by cytokinin discoveries in all kingdoms of life. However, understanding of their role in mammalian cells is still scarce. Kinetin is a cytokinin that mitigates the effects of oxidative stress in mammalian cells. The effective concentrations of exogenously applied kinetin in invoking various cellular responses are not well standardized. Likewise, the metabolism of kinetin and its cellular targets within the mammalian cells are still not well studied. Applying vitality tests as well as comet assays under normal and hyper-oxidative states, our analysis suggests that kinetin concentrations of 500 nM and above cause cytotoxicity as well as genotoxicity in various cell types. However, concentrations below 100 nM do not cause any toxicity, rather in this range kinetin counteracts oxidative burst and cytotoxicity. We focus here on these effects. To get insights into the cellular targets of kinetin mediating these pro-survival functions and protective effects we applied structural and computational approaches on two previously testified targets for these effects. Our analysis deciphers vital residues in adenine phosphoribosyltransferase (APRT) and adenosine receptor (A2A-R) that facilitate the binding of kinetin to these two important human cellular proteins. We finally discuss how the therapeutic potential of kinetin against oxidative stress helps in various pathophysiological conditions.
Aims
Chronic heart failure (CHF) can be caused by autoantibodies stimulating the heart via binding to first and/or second extracellular loops of cardiac β1-adrenoceptors. Allosteric receptor activation depends on conformational features of the autoantibody binding site. Elucidating these features will pave the way for the development of specific diagnostics and therapeutics. Our aim was (i) to fine-map the conformational epitope within the second extracellular loop of the human β\(_1\)-adrenoceptor (β1ECII) that is targeted by stimulating β\(_1\)-receptor (auto)antibodies and (ii) to generate competitive cyclopeptide inhibitors of allosteric receptor activation, which faithfully conserve the conformational auto-epitope.
Methods and results
Non-conserved amino acids within the β\(_1\)EC\(_{II}\) loop (compared with the amino acids constituting the ECII loop of the β\(_2\)-adrenoceptor) were one by one replaced with alanine; potential intra-loop disulfide bridges were probed by cysteine–serine exchanges. Effects on antibody binding and allosteric receptor activation were assessed (i) by (auto)antibody neutralization using cyclopeptides mimicking β1ECII ± the above replacements, and (ii) by (auto)antibody stimulation of human β\(_1\)-adrenoceptors bearing corresponding point mutations. With the use of stimulating β\(_1\)-receptor (auto)antibodies raised in mice, rats, or rabbits and isolated from exemplary dilated cardiomyopathy patients, our series of experiments unmasked two features of the β\(_1\)EC\(_{II}\) loop essential for (auto)antibody binding and allosteric receptor activation: (i) the NDPK\(^{211–214}\) motif and (ii) the intra-loop disulfide bond C\(^{209}\)↔C\(^{215}\). Of note, aberrant intra-loop disulfide bond C\(^{209}\)↔C\(^{216}\) almost fully disrupted the functional auto-epitope in cyclopeptides.
Conclusions
The conformational auto-epitope targeted by cardio-pathogenic β\(_1\)-receptor autoantibodies is faithfully conserved in cyclopeptide homologues of the β\(_1\)EC\(_{II}\) loop bearing the NDPK\(^{211–214}\) motif and the C\(^{209}\)↔C\(^{215}\) bridge while lacking cysteine C216. Such molecules provide promising tools for novel diagnostic and therapeutic approaches in β\(_1\)-autoantibodypositive CHF.